Stephan Stilgenbauer

Stephan Stilgenbauer

UNVERIFIED PROFILE

Are you Stephan Stilgenbauer?   Register this Author

Register author
Stephan Stilgenbauer

Stephan Stilgenbauer

Publications by authors named "Stephan Stilgenbauer"

Are you Stephan Stilgenbauer?   Register this Author

100Publications

4024Reads

13Profile Views

Response to Comment by Jonathan Weiss

Haematologica 2019 Nov;104(11):e542

Internal Medicine III, Ulm University, Ulm. Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.236570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821624PMC
November 2019

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Leukemia 2019 10 14;33(10):2531-2535. Epub 2019 May 14.

Department of Medicine V, University Hospital Heidelberg, Department of Molecular Therapy in Haematology & Oncology, NCT/DKFZ, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0475-zDOI Listing
October 2019

Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.

Br J Haematol 2019 Sep 1;186(6):e203-e207. Epub 2019 Jul 1.

Internal Medicine I, Saarland University Medical School, Homburg, Saarland, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16082DOI Listing
September 2019

PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.

Leukemia 2019 06 20;33(6):1427-1438. Epub 2018 Dec 20.

Department of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0318-3DOI Listing
June 2019

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

N Engl J Med 2019 Jun 4;380(23):2225-2236. Epub 2019 Jun 4.

From Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne (K.F., O.A.-S., J.B., A.-M.F., S. Robrecht, B.E., K.-A.K., M.H.), the Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital (V.G.), CECAD (Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases) (M.H.), Center for Molecular Medicine Cologne (M.H.), Cologne, Department III of Internal Medicine, University Hospital Rostock, Rostock (S.B.), Department III of Internal Medicine, Ulm University, Ulm (E.T., S.S.), the Departments of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich (C.-M.W.), Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel (M.R.), and the Department of Hematology, Oncology, and Rheumatology, Saarland University Medical School, Homburg (S.S.) - all in Germany; Roche Products, Welwyn Garden City, United Kingdom (M.T., M.D., S.W., K.H.); Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russia (O.S.); the Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy (A.M.L.); the Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.P.-I.); the Haematology Department, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (S.O.); First Internal Department, Multiprofile Hospital for Active Treatment Hristo Botev, Vratsa, Bulgaria (L.S.); the Hematology Department, Clinique Victor Hugo, Le Mans, France (K.L.D.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (L.M.F.); the Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (C.U.N.); Wellington Blood and Cancer Centre, Capital and Coast District Health Board, and Malaghan Institute of Medical Research, Wellington, New Zealand (R.W.); Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (S. Robinson); Moores Cancer Center, University of California San Diego, San Diego (T.J.K.), and Genentech, South San Francisco (M.M.) - both in California; AbbVie, North Chicago, IL (R.H.); and the Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands (A.W.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1815281
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1815281DOI Listing
June 2019

Targeted therapy in CLL: changing the treatment paradigm.

Oncotarget 2019 Jun 18;10(40):4002-4003. Epub 2019 Jun 18.

Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592289PMC
June 2019

Venetoclax: Targeting BCL2 in Hematological Cancers.

Recent Results Cancer Res 2018;212:215-242

Department of Internal Medicine III, Ulm University, Albert Einstein Allee 23, 89081, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-91439-8_11DOI Listing
May 2019

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

Leukemia 2019 05 19;33(5):1161-1172. Epub 2018 Dec 19.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, CECAD Cluster of Excellence at the University of Cologne, Clinical Research Unit (KFO) 286, German CLL Study Group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0313-8DOI Listing
May 2019

From Biology to Therapy: The CLL Success Story.

Hemasphere 2019 Apr 9;3(2):e175. Epub 2019 Feb 9.

Department of Internal Medicine III, Ulm University, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746030PMC
April 2019

aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Haematologica 2018 12 15;103(12):1956-1968. Epub 2018 Nov 15.

Internal Medicine III, Ulm University, Germany and Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany.

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.187583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269313PMC
December 2018

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Br J Haematol 2018 12 21;183(5):727-735. Epub 2018 Nov 21.

Department I of Internal Medicine and Centre of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15604DOI Listing
December 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Future Oncol 2018 Mar 21;14(6):499-513. Epub 2018 Feb 21.

Department I of Internal Medicine & Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0442DOI Listing
March 2018

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Clin Cancer Res 2017 Aug 18;23(16):4527-4533. Epub 2017 Jan 18.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0955DOI Listing
August 2017

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.

J Oncol Pract 2017 06;13(6):381-382

Ulm University, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.024562DOI Listing
June 2017

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Eur J Haematol 2017 Mar 1;98(3):254-262. Epub 2016 Dec 1.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12825DOI Listing
March 2017

Ibrutinib-resistant CLL: unwanted and unwonted!

Blood 2017 03;129(11):1407-1409

UNIVERSITY ULM.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-761536DOI Listing
March 2017

Front-line treatment of CLL in the era of novel agents.

Cancer Treat Rev 2017 Feb 30;53:70-78. Epub 2016 Dec 30.

Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.12.007DOI Listing
February 2017

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.

Onco Targets Ther 2017 7;10:645-656. Epub 2017 Feb 7.

Department of Internal Medicine III, Ulm University, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S102646DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308588PMC
February 2017

Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lympocytic leukemia?

Leuk Lymphoma 2017 01 22;58(1):6-7. Epub 2016 Aug 22.

a Department of Internal Medicine III , University of Ulm , Ulm , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1213837DOI Listing
January 2017

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.

Oncol Res Treat 2016 26;39(1-2):34-40. Epub 2016 Jan 26.

Department of Internal Medicine III, Ulm University, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000443906DOI Listing
December 2016

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

J Clin Oncol 2016 11;34(31):3758-3765

Gabor Kovacs, Sandra Robrecht, Anna Maria Fink, Jasmin Bahlo, Paula Cramer, Julia von Tresckow, Christian Maurer, Petra Langerbeins, Kirsten Fischer, Michael Hallek, and Barbara Eichhorst, University of Cologne and Center of Integrated Oncology Cologne/Bonn, Cologne; Matthias Ritgen, Michael Kneba, and Sebastian Böttcher, University of Schleswig-Holstein, Lubeck; Hartmut Döhner and Stephan Stilgenbauer, University of Ulm, Ulm; Wolfram Klapper, University of Kiel, Kiel; Clemens-Martin Wendtner, Klinikum Schwabing, Munich, Germany; and Günter Fingerle-Rowson, F. Hoffmann La-Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1305DOI Listing
November 2016

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Oncoimmunology 2016 Jun 22;5(6):e1150399. Epub 2016 Apr 22.

1st Department of Internal Medicine and Center for Integrated Oncology CIO Köln/Bonn, University Hospital of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner site Bonn-Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1150399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938364PMC
June 2016

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

J Clin Oncol 2016 Apr 29;34(12):1386-94. Epub 2016 Feb 29.

Eva Hoster, Roswitha Forstpointner, Christian Schmidt, Wolfgang Hiddemann, Michael Unterhalt, and Martin H. Dreyling, University Hospital Munich; Eva Hoster, University of Munich, Munich; Andreas Rosenwald, University of Würzburg, Würzburg; Heinz-Wolfram Bernd, University Hospital Schleswig-Holstein, Lübeck; Sylvia Hartmann, University Hospital of Frankfurt, Frankfurt am Main; Christoph Loddenkemper, University Hospital Berlin Charité; Christoph Loddenkemper, Pathologie PathoTres, Berlin; Thomas F.E. Barth, University Medical Center Ulm; Stephan Stilgenbauer, University of Ulm, Ulm; Michael Hallek, Universität zu Köln, Köln; Ursula Vehling-Kaiser, Tagesklinik Hämatologie Onkologie, Landshut; Lothar Kanz, University of Tübingen, Tübingen; Michael Pfreundschuh, Universitätsklinik des Saarlandes, Homburg; Wolfram Klapper, University of Kiel, Kiel, Germany; Françoise Berger, LYSA Group; Nicole Brousse, Hopital Necker; Catherine Thieblemont, Hôpital Saint Louis; Olivier Hermine, University Paris Descartes; Olivier Hermine, Université Sorbonne Paris Cité, Paris; Bertrand Coiffier, Centre Hospitalier Lyon-Sud, Pierre-Bénite; Réda Bouabdallah, Service d'Hématologie, Marseille; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Stefano Pileri, University of Bologna, Bologna, Italy; Grzegorz Rymkiewicz, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Roman Kodet, Charles University, Prague, Czech Republic; and Johanna C. Kluin-Nelemans, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.8387DOI Listing
April 2016